/stocks — the workspaceLOADING
All SUPN SEC filings, by type → · Earnings date & implied move · Search inside filings
SUPERNUS PHARMACEUTICALS, INC. (SUPN) is a pharmaceutical preparations company. Piotroski F-Score 3/7. 10 insider Form 4 filings in the last 90 days. Next earnings confirmed for 2026-10-29 (SEC filing). Fundamentals from SEC filings; prices are end-of-day.
What’s behind SUPN’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
Stage-1 growth down the side, discount rate across the top, with terminal growth at 2.5% and 10 years of stage 1. Every cell runs the same two-stage DCF as the card above, so moving a slider moves the grid.
| Growth ↓ Discount → | 7% | 8% | 9% | 10% | 11% |
|---|---|---|---|---|---|
| 4% | 20.35 | 16.58 | 13.97 | 12.06 | 10.60 |
| 6% | 23.92 | 19.38 | 16.25 | 13.96 | 12.21 |
| 8% | 28.11 | 22.66 | 18.90 | 16.16 | 14.08 |
| 10% | 33.00 | 26.48 | 21.99 | 18.73 | 16.25 |
| 12% | 38.72 | 30.93 | 25.58 | 21.70 | 18.75 |
| Growth the close implies | 12.6% | 15.6% | 18.2% | 20.6% | 22.8% |
Outlined: your current pair. Shaded: at or above the last close, 40.70 USD. The heavy line runs between the cells on either side of it.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from SUPN’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on SUPN plus an auto-SWOT — built from SUPN's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate SUPN using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has SUPN been issuing shares? Offering history →
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as SUPN tagged it: revenue us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
No lawmaker has disclosed a trade in SUPN under the STOCK Act.
This date and time was extracted directly from SUPN's own Form 8-K (earnings press release) filed with the U.S. Securities and Exchange Commission — not an analyst estimate or a third-party calendar. We mark a report “confirmed” only when the company itself has stated the date in a public SEC filing, and we link that filing above so you can verify it. Everything else stays an honest estimate from the company's filing cadence. From filings, not guesses.
Projected from SUPN's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentSUPN files or announces.
SUPN's earnings reaction has been evenly split — 4 up, 4 down across its last 8 reports.
Each figure is one earnings reaction — how much SUPN moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Large earnings reactions have been common.
The average is inflated by its most volatile prints (+14.5% and -15.4%).
A more typical earnings reaction has been approximately ±5.1%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-03 | -3.1% |
| 2026-05-05 | +5.8% |
| 2026-02-24 | +11.1% |
| 2025-11-04 | -15.4% |
| 2025-08-05 | +14.5% |
| 2025-05-06 | -4.5% |
| 2025-02-25 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -2.4% |
| 2024-11-04 | +2.3% |
1 of 5 estimators could run on SUPN's filings. A band needs at least 2.
One estimator is a point estimate, not a range, so no band and no valuation label are published for SUPN. Below is everything that was checked, so the refusal can be read rather than taken on trust.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for SUPN, so sector medians could not fill the gaps.
Every refusal recorded for SUPN → · How often we decline, and why →
No tracked institution reported a position in SUPN in the latest 13F round.
Every registered fund files its complete portfolio with the SEC. These weights come from those filings, so each one carries the period it describes. Holdings are quarterly and filed in arrears — the figures below are as of 2026-06-30, not today.
| Fund | Weight | As of |
|---|---|---|
| IJR iShares Core S&P Small-Cap ETF | 0.15% | 2026-06-30 |
| IWM iShares Russell 2000 ETF | 0.08% | 2026-06-30 |
| ITOT iShares Core S&P Total US Stock Market ETF | <0.01% | 2026-06-30 |
| VTI Vanguard Total Stock Market ETF | <0.01% | 2026-06-30 |
Drawn from 39 large US equity funds we scan, not every fund in existence, so a missing fund means we do not scan it rather than that it holds none. Holdings are joined to tickers by issuer name, which does not resolve every position; what that misses is published.
Head office: Rockville, Maryland, United States · the company’s charter and its head office are in different states.
Source: the cover page of SUPERNUS PHARMACEUTICALS, INC.’s 10-Q filed 2026-08-03, on EDGAR. Filings checked 2026-10-24. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
No open-market Form 4 buys or sells reported for SUPN in the last ~6 months.
2 of the 2 checks that ran found nothing new for SUPN. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
Every figure is from SUPN’s SEC cash-flow statement. This describes how management deployed cash last period — it is not a grade of that deployment, not a forecast, and not investment advice. Whether reinvesting, paying down debt, or returning cash was the right call depends on the return each earns, which the filings do not settle. Educational information only.